Nazartinib; EGF816; NVS-816
Cikakken Bayani
Tags samfurin
| Girman Kunshin | samuwa | Farashin (USD) |
| 25mg ku | A Stock | 290 |
| 50mg | A Stock | 450 |
| 100mg | A Stock | 630 |
| 1g | A Stock | 1600 |
| Ƙarin Girman Girma | Samu Magana | Samu Magana |
Sunan Sinadari:
(R,E)-N-(7-chloro-1-- (1- (4- (dimethylamino)amma-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl) 2-methylisonicotinamide
Lambar SMILES:
O=C(NC1=NC2=CC=CC(Cl)=C2N1[C@H]3CN(C(/C=C/CN(C)C)=O)CCCC3)C4=CC=NC(C)= C4
Lambar InChi:
InChi=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33( 26)20-8-4-5-15-32 (17-20)23 (34)11-7-14-31 (2)3/h6-7,9-13,16,20H,4-5, 8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1
InChi Key:
IOMMMLWIABWRKL-WUTDNEBXSA-N
Mabuɗin kalma:
Nazartinib, EGF816, EGF-816, EGF 816, NVS-816, 1508250-71-2
Solubility:Mai narkewa a cikin DMSO
Ajiya:0 - 4 ° C na gajeren lokaci (kwanaki zuwa makonni), ko -20 ° C na dogon lokaci (watanni)
Bayani:
Nazartinib, wanda kuma aka sani da EGF816 da NVS-816, samuwa ne ta baki, ba za a iya jurewa ba, tsararraki na uku, mai hana mai karɓar haɓakar haɓakar haɓakar mutant (EGFR), tare da yuwuwar aikin antineoplastic. EGF816 covalently yana ɗaure kuma yana hana ayyukan mutant siffofin EGFR, gami da mutant T790M EGFR, ta haka yana hana siginar tsaka-tsakin EGFR. Wannan na iya haifar da mutuwar tantanin halitta kuma yana hana haɓakar ƙwayar cuta a cikin EGFR-masu wuce gona da iri. EGF816 ya fi dacewa yana hana sauye-sauyen nau'ikan EGFR ciki har da T790M, maye gurbin juriya na biyu, kuma yana iya samun fa'idodin warkewa a cikin ciwace-ciwacen daji tare da juriya mai matsakaicin T790M idan aka kwatanta da sauran masu hana EGFR tyrosine kinase.
Saukewa: EGFR
